boxy, O-carboxy, sulfonamido, guanyl, guanidinyl, hydrazine, hydrazide, thiohydrazide, and amino,

wherein when R<sub>2</sub> is hydrogen, the dashed line represents an unsaturated bond.

and wherein R<sub>1</sub> is not phenyl, 2,4,6-trimethylphenyl, 4-trifluoromethylphenyl, 4-chlorophenyl or 2,6-dichlorophenyl.

- 15. The compound of claim 14, wherein the dashed line represents an unsaturated bond.
  - 16. The compound of claim 15, wherein R<sub>2</sub> is hydrogen.
- 17. The compound of claim 14, wherein  $\bar{R}_2$  is selected from the group consisting of hydrogen, halo and O-carboxy.
- 18. The compound of claim 14, wherein  $R_1$  is a substituted or non-substituted aryl or a substituted or non-substituted indolyl.
- 19. The compound of claim 14, wherein said aryl or heteroaryl is substituted by one or more electron withdrawing groups.
- 20. The compound of claim 19, wherein said electron withdrawing groups are halo.
- 21. The compound according to claim 14, wherein  $R_1$  is a substituted phenyl.
- **22**. A method of inhibiting nuclear translocation of ERK1/2 in a cell, the method comprising contacting the cell with a compound represented by Formula I or Formula II:

Formula I

$$R_1$$
  $R_2$   $R_2$   $R_3$   $R_4$   $R_5$   $R_6$   $R_7$ 

Formula II

$$\mathbb{R}'_1 \longrightarrow \mathbb{Q} \longrightarrow \mathbb{R}'_2$$

wherein:

each dashed line independently represents a saturated or unsaturated bond;

R<sub>1</sub> and R'<sub>1</sub> are each independently an aryl or heteroaryl, which is substituted or non-substituted; and

R<sub>2</sub> and R¹<sub>2</sub> are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, sulfonate, sulfate, cyano, nitro, azide, phosphonyl, phosphinyl, carbonyl, thiocarbonyl, a urea group, a thiourea group, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, C-carboxy, O-carboxy, sulfonamido, guanyl, guanidinyl, hydrazine, hydrazide, thiohydrazide, and amino,

wherein when R<sub>2</sub> is hydrogen, the dashed line in Formula I represents an unsaturated bond, and when R'<sub>2</sub> is hydrogen, the dashed line in Formula II represents an unsaturated bond,

thereby inhibiting the nuclear translocation of ERK1/2.

- 23. The method of claim 22, being effected ex vivo.
- 24. The method of claim 22, wherein said dashed line represents an unsaturated bond.
- 25. The method of claim 24, wherein  $R_2$  and  $R'_2$  are hydrogen.
- **26**. The method of claim **22**, wherein  $R_2$  and  $R'_2$  are each independently selected from the group consisting of hydrogen, halo and O-carboxy.
- **27**. The method of claim **22**, wherein  $R_1$  and  $R'_1$  are each independently a substituted or non-substituted aryl or a substituted or non-substituted indolyl.
- **28**. The method of claim **22**, wherein said aryl or heteroaryl is substituted by one or more electron withdrawing groups.
- 29. The method of claim 28, wherein said electron with-drawing groups are halo.
- **30**. The method of claim **22**, wherein  $R_1$  and  $R'_1$  are each independently phenyl.

\* \* \* \* \*